A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Trial Profile

A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Plasma cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 17 Nov 2016 Results published in the New England Journal of Medicine
    • 14 Jul 2016 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top